Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarker Tied To Success Of GlobeImmune's Therapeutic Hep C Vaccine In Patients With Poor Prognosis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Positive Phase II results for GlobeImmune's immune-boosting hepatitis C vaccine GI-5005 were underscored at the European Association for the Study of the Liver meeting in Vienna April 17 by results from a newly available biomarker test that shows the therapy is most effective at clearing the virus from patients whose genetic status predicts little chance for complete recovery

You may also be interested in...



GlobeImmune’s Hep C Vaccine Posts Positive Phase II Data

GlobeImmune responds to calls to “show me the data,” increasing its chances of a partnership.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals

Product

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel